← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-12 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
ADCBiologicstaleZhengda Tianqing Pharmaceutical…Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+AK105+cisplatin)

Advanced Gastric Carcinoma; HER2-positive Gastric Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
ADCBiologicstaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Furmonertinib, 1L)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Furmonertinib, 2L+)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleChanghai HospitalPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+PD-1+platinum-based)

Esophageal Squamous Carcinoma; HER-2 Protein Overexpression · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
AntibodystaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Tislelizumab+carboplatin)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRegeneronPhase 2

REGN15505+Cemiplimab (REGN15505+Cemiplimab)

Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) · Metastatic Castration-Resistant Prostate

#MetastaticCastration-ResistantPr#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSanofiPhase 2

REGN3500 + Dupilumab Combo (REGN3500 + Dupilumab Combo)

Atopic Dermatitis · Atopic Dermatitis

#AtopicDermatitis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleRegeneron PharmaceuticalsPhase 1

REGN5093-M114 (REGN5093-M114)

Advanced NSCLC · Advanced NSCLC

#AdvancedNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 DISCONTINUED
ADCBiologicstaleOu Bai, MDPhase 2

RMTO (RMTO)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

RNA anti-CD19 CAR T cells (RNA anti-CD19 CAR T cells)

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
AntibodystaleHoffmann-La RochePhase 1

RO5323441 + bevacizumab [Avastin] (RO5323441 + bevacizumab [Avastin])

Glioblastoma Multiforme · Glioblastoma Multiforme

#GlioblastomaMultiforme#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 1

atezolizumab (Tecentriq, RO7567132 and Atezolizumab)

Cancer-Neoplasms · Cancer-Neoplasms

#Cancer-Neoplasms#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
CGTBiologicstaleFred Hutchinson Cancer CenterPhase 1

ROR1 CAR-specific Autologous T-Lymphocytes (ROR1 CAR-specific Autologous T-Lymphocytes)

Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 0%임상시험 1상태 DISCONTINUED
CGTBiologicstaleReplimune, Inc.Phase 2

RP1, intra-tumoral injection, oncolytic virus (RP1, intra-tumoral injection, oncolytic virus)

Merkel Cell Carcinoma; Basal Cell Carcinoma · Merkel Cell Carcinoma

#MerkelCellCarcinoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleEden BioCell Ltd.Phase 1

RPM CD19-mbIL15-CAR-T cells (RPM CD19-mbIL15-CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma, Relapsed · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 DISCONTINUED
AntibodystaleAssociazione Volontari Pazienti…Phase 3

RT+CETUXIMAB (RT+CETUXIMAB)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleArtielle ImmunoTherapeuticsPhase 1

recombinant T cell receptor ligand (RTL1000, RTL1000 (recombinant T cell receptor ligand))

Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Chronic Progressive

#MultipleSclerosisChronicProgress#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 2%임상시험 1상태 ACTIVE
AntibodystaleEli Lilly and CompanyPhase 1

IMC-1121B (Ramucirumab, Ramucirumab (IMC-1121B))

Colorectal Carcinoma · Colorectal Carcinoma

#ColorectalCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJiangsu HengRui Medicine Co., L…Phase 3

Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING

146 / 177 페이지

← 이전다음 →